Close menu




February 10th, 2022 | 11:14 CET

BioNTech, Cardiol Therapeutics, Peloton: Future check on pandemic stocks

  • Biotechnology
Photo credits: pixabay.com

There are pandemic stocks that are already out today. But there are also pandemic stocks that are only now taking off operationally. We take a look at three stocks and do a future check: Where has the pandemic only provided the initial spark, and where is the hype irretrievably over?

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006 , PELOTON INTE.A DL-_000025 | US70614W1009

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNTech: What comes after Omicron?

    The BioNTech share has lost around 25% of its value in the past month alone. Over the course of a year, the stock is only up about 40%. Why did the mRNA hopeful take such a beating? The Omicron wave is both a blessing and a curse for BioNTech investors. In the beginning, the variant gave hope that new vaccines would be needed. In the meantime, it seems as if Omicron could pass so easily that an annual administration to particularly vulnerable groups will be sufficient in the future, similar to the flu.

    In the meantime, almost every German has been able to get a glimpse of the Omicron course. Fortunately, Omicron is comparatively mild for those who have basic immunization. More and more people in a circle of acquaintances report symptoms that would not have had any consequences in 2019 - apart from a pack of tissues in their pocket. But it is a mistake to extrapolate personal experiences and draw generalized conclusions from them. In the end, studies will have to show how dangerous Omicron really is. That the results will give hope, however, already seems certain. BioNTech has long been focusing on new targets anyway and has set its sights on vaccines against cancer. The Company remains well positioned, has gained a lot of experience and trust in the market due to the pandemic, and will remain an important biotech player in the future. For investors, however, a turnaround is needed first. BioNTech remains a pandemic beneficiary with limitations.

    Cardiol Therapeutics - A matter of the heart

    While BioNTech has already put its horsepower on the road, Canadian biotech Cardiol Therapeutics is on the starting grid with its engine revving. The Company uses cannabinoids (CBD) in unique formulations to treat inflammatory diseases of the heart. Studies to date show that the effects of heart muscle inflammation can be well treated. In a research article by researchanalyst.com, the authors attest Cardiol Therapeutics a promising perspective: "The analysts' price targets range between CAD 5 and CAD 17.49 with an average price target of CAD 11. If one takes the lower limit of this target range, the shares have the potential to quadruple," the authors say.

    The possibility of a takeover should not be neglected either. Currently, the Company is valued at only about CAD 170 million. "Cardiol, compared to the billion-dollar acquisitions made in the past, is a lightweight. Recently, US company Pfizer swallowed California-based Arena Pharmaceuticals for USD 6.7 billion. Arena has yet to bring a drug to market," according to researchanalyst.com. To assess the further prospects of the Nasdaq-listed biotech Company, investors should make a note of the International Investment Forum (IIF) virtual event. Cardiol CEO David Elsley will present the Company and answer the audience's questions live.

    Peloton: End of the line for broom wagons?

    Those responsible for the indoor training startup Peloton are likely to be somewhat speechless when asked about their plans to turn the tide. Peloton offers a smart spinning bike that provides coaching via video stream. Most recently, the former success story has faltered significantly, with Peloton CEO John Foley forced to leave and one-fifth of the jobs eliminated. Peloton may put more emphasis on selling subscriptions in the future rather than expensive hardware. In the past, the expensive Peloton bike was often an obstacle to convince customers in the first place. Recreational athletes, in particular, who have been runners or are just getting into the sport, may have been put off by four-figure sums. The share price has reacted positively to the latest personnel development, but this is far from a turnaround.


    While Peloton may have seen its best days at the start of the pandemic, BioNTech still has potential beyond the epidemic. The mRNA technology is too powerful to be forgotten. Both in and out of the pandemic, heart disease plays a significant role in health risks in developed countries. Cardiol Therapeutics may be in its infancy, but it has already performed well in many areas. The share, therefore, holds a lot of interest. On February 17, interested parties can hear the CEO explain the business model live.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read

    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?

    Read

    Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

    MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

    • Biotechnology
    • Pharma

    Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.

    Read